Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s
Novartis to build fourth US radiotherapy factory in Florida
Novartis to build fourth US radiotherapy factory in Florida
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A
Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A
Roche and Novartis close to price agreement with Trump - medwatch.com
Roche and Novartis close to price agreement with Trump - medwatch.com
Voyager jettisons 30 employees, Novartis hands back rights to 2 programs
Voyager jettisons 30 employees, Novartis hands back rights to 2 programs
Novartis notches another win for drug acquired in MorphoSys deal
Novartis notches another win for drug acquired in MorphoSys deal
Novartis to partner with AI-focused Relation on atopic diseases
Novartis to partner with AI-focused Relation on atopic diseases
ASH: Novartis details ianalumab's phase 3 win in rare blood disease
ASH: Novartis details ianalumab's phase 3 win in rare blood disease
FDA raises CAR-T approval standards; Novartis bets on an AI startup
FDA raises CAR-T approval standards; Novartis bets on an AI startup
Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech
Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech
#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
#ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment
Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment
Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
Novartis wins approval to use SMA gene therapy in older patients
Novartis wins approval to use SMA gene therapy in older patients
Novartis was the sole bidder in $12B deal to buy Avidity
It took 14 calls between chief executives, four months of negotiations and four hiked proposals for Novartis and Avidity Biosciences to come to their $12 billion agreem...
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins
Late-breaking abstracts from the annual American Society of Hematology meeting are early this year, coming right before Thanksgiving instead of the previously planned d...